CrossAssetDataThe Company File
···
ANIP

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Baudette, MN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $883 million and a profit of $77 million (its filed statements).

Product business Pharmaceutical Preparations Baudette, MN filings since 1999 9 of 9 filed
Ask the desk about ANIP → Compare ANIP with SUPN → Price chart on TradingView ↗ Full EDGAR file ↗ Watch ANIP →

Sector peers: SUPNCYTKARWRPAHC

6.2/10headline grade
vs its business-model standard
6.1/10past 6.6/10present 5.7/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.2 out of ten, 9 of 9 metrics filed: past 6.1 out of ten, present 6.6 out of ten, future 5.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 4.1 out of ten. 2 warning events since 2017; the latest 2026-04-07. 41st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 8.2 out of ten. +23.9% a year over 10 filed years; profitable in 5 of 10. 82nd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 4.9 out of ten. Share count grew 9.3% a year. 9% of cash flow returned. Insiders: 48 sales, 0 purchases. 49th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.9 out of ten. ROE 14%: 14¢ of profit per shareholder dollar. Leverage 62%: owes 62¢ per asset dollar. 59th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 8.1 out of ten. top 19% of 314 in its family; net margin 8.7%. 81st percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.7 out of ten. top 43% of 315 in its family for leadership; chief executive since 2020. 57th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.5 out of ten. bottom 35% of 272 in its family for room to expand. 35th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 7.9 out of ten. top 21% of 307 in its family for growth drivers. 79th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 7.0 out of ten. top 30% of 234 in its family for expectations against reality. 70th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-27 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-07 (on EDGAR). Newest filing: Form 4, 2026-09-30. Filings on record since 1999. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Sales of Generic Pharmaceutical Products 44%, Sales of Cortrophin Gel 39%, Sales of ILUVIEN and YUTIQ 9%, Sales of Established Brands 7%, Sales of Royalties and Other Pharmaceutical Services 2%. By geography: United States 97%, International 4%. As tagged in its annual report (Form 10-K, filed 2026-02-27).

Who runs it

Lalwani, Nikhil (PRESIDENT & CEO); Walsh, Patrick D (CHAIRMAN, INTERIM PRES. & CEO); Carey, Stephen P. (SVP & CFO); Shanmugam, Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS); Davis, Krista (SVP, CHIEF HR OFFICER); Cook, Meredith (SR. VP, GENERAL COUNSEL & SEC.); Gutwerg, Ori (SVP, GENERICS); Rowland, Thomas Andrew (SVP, HEAD - ESTABLISHED BRANDS); Mutz, Christopher (HEAD OF RARE DISEASE); Gassert, Chad (SVP - CORP. DEV. & STRATEGY); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.